Creative Medical Technology Holdings Inc (CELZ) Stock Price, Quote & News

Company Profile

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized super...

Industry: Biotechnology

Sector: Healthcare

Phone: 480 399 2822

Website: www.creativemedicaltechnology.com

Address:

211 East Osborn Road, Phoenix, United States

PraxisTrade Jun. 8 at 12:04 PM

$ICU $PLBY $CELZ $CX ss

0 · Reply

FroNOBaggins Jun. 2 at 8:07 PM

$CELZ hasn't been good with investor communication, so I'm gonna speculate. 🤷 Per the CTDG posting, the original primary completion estimate for the CELZ-201-DDT Adapt trial was 10.1.25. CELZ then released its positive ADAPT update on 1/13/26 (~10 weeks later) The estimated primary completion with the expanded study was estimate 5.1.26. Using the prior cadence as a rough guide, the next meaningful ADAPT (which is a more serious design than many small biotech programs at this stage) update might fall somewhere in the July to August 2026. Available data suggests ADAPT is moving in the right direction (clean safety profile + encouraging improvement in both pain and function). If the next data update strengthens the January news and P3 becomes increasingly likely this could get real interesting quick. This is still early data, communication has been underwhelming at best, dilution risk is high, and still a long way to go (but possible acquisition would become increasingly likely).

0 · Reply

Bobby_J_Bomb May. 30 at 1:57 PM

$CELZ right now,the next major catalyst could be phase 3 enabling data. This isnt like previous spikes,this would be a game changer and a true path to legitimacy.

1 · Reply

tonneke May. 28 at 4:30 PM

$CELZ My average is $2.06, is that low or ???? 🤷‍♂️

3 · Reply

tonneke May. 27 at 10:19 AM

$CELZ A little bit of news would be nice. 🥳🎉

1 · Reply

H177 May. 22 at 4:44 PM

$CELZ

0 · Reply

H177 May. 22 at 4:42 PM

$CELZ

0 · Reply

tonneke May. 22 at 2:06 PM

$CELZ slowly but still

0 · Reply

Peterb3346 May. 22 at 1:45 PM

$CELZ finally starting to get interesting

0 · Reply

H177 May. 19 at 11:40 PM

$CELZ https://www.biodefenseinc.com/

2 · Reply

Creative Medical knee data ‘highly positive,’ says Roth Capital

2026-04-28T13:57:36.000Z - 5 weeks ago

Creative Medical reports pilot study of Ultrasome meets priamry endpoint

Apr 28, 2026, 9:01 AM EDT - 5 weeks ago

Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies

2026-02-10T14:06:26.000Z - 4 months ago

Creative Medical achieves second WHO INN milestone

2026-01-13T14:25:23.000Z - 5 months ago

Creative Medical announces interim data from ADAPT trial of CELZ-201

Jan 13, 2026, 9:15 AM EST - 5 months ago

Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain

2026-01-06T14:25:33.000Z - 5 months ago

Creative Medical receives regulatory approval for BioDefense Burn Pit Initiative

Jan 6, 2026, 9:15 AM EST - 5 months ago

Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative

2025-12-17T14:20:20.000Z - 6 months ago

Creative Medical completes enrollment in ADAPT trial for CELZ-201

Dec 17, 2025, 9:15 AM EST - 6 months ago

Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point

2025-12-02T14:25:30.000Z - 6 months ago

Creative Medical announces WHO approval of olastrocel as INN for CELZ-201

Dec 2, 2025, 9:15 AM EST - 6 months ago

Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201

2025-10-30T13:20:14.000Z - 7 months ago

Creative Medical launches Biodefense Inc. Veterans Initiative

Oct 30, 2025, 9:15 AM EDT - 7 months ago

Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits

2025-10-29T13:10:43.000Z - 7 months ago

Creative Medical announces agreements for warrant exercise for $4.2M proceeds

Oct 29, 2025, 9:00 AM EDT - 7 months ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds

2025-10-27T12:30:51.000Z - 8 months ago

Creative Medical issues letter to shareholders

Oct 27, 2025, 8:15 AM EDT - 8 months ago

Creative Medical Technology Holdings Issues Letter to Shareholders

Oct 7, 2025, 9:15 AM EDT - 8 months ago

Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs

2025-08-13T13:10:11.000Z - 10 months ago

Creative Medical secures FDA Fast Track designation for CELZ-201-DDT

2025-07-17T13:20:53.000Z - 11 months ago

Creative Medical receives notice of allowance for prevention, treatment of T1D

Jul 17, 2025, 9:15 AM EDT - 11 months ago

Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells

2025-07-11T12:10:13.000Z - 11 months ago

Creative Medical receives notice of allowance for ImmCelz

Jul 11, 2025, 8:01 AM EDT - 11 months ago

Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling

2025-06-04T16:06:21.000Z - 1 year ago

Creative Medical price target lowered to $20 from $26 at Roth Capital

2025-04-02T20:50:13.000Z - 1 year ago

Creative Medical Technology files to sell 1.8M shares of common for holders

2025-03-21T12:30:45.000Z - 1 year ago

Creative Medical Technology price target lowered to $26 from $30 at Roth MKM

2025-03-20T11:55:49.000Z - 1 year ago

Creative Medical secures FDA clearance for dose escalation in Phase 1/2 trial

Mar 20, 2025, 7:50 AM EDT - 1 year ago

Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain

2025-03-06T13:28:04.000Z - 1 year ago

Creative Medical announces agreements for exercise of warrants

Mar 6, 2025, 8:10 AM EST - 1 year ago

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds

2025-02-20T13:31:55.000Z - 1 year ago

Creative Medical Technology comments on presidential initiative for IVF access

Feb 14, 2025, 7:00 AM EST - 1 year ago

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

Feb 11, 2025, 9:25 AM EST - 1 year ago

Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program

Feb 5, 2025, 8:25 AM EST - 1 year ago

Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

Jan 30, 2025, 9:25 AM EST - 1 year ago

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Nov 13, 2024, 9:00 AM EST - 1 year ago

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

Jul 24, 2024, 9:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

Jul 10, 2024, 8:30 AM EDT - 2 years ago

Creative Medical Technology Holdings Provides Corporate Update

Jun 24, 2024, 8:30 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Mar 7, 2024, 9:15 AM EST - 2 years ago

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

Mar 6, 2024, 7:00 AM EST - 2 years ago

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Dec 20, 2023, 9:35 AM EST - 2 years ago

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

Oct 10, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain

Aug 24, 2023, 10:45 AM EDT - 3 years ago

What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?

Jul 14, 2023, 9:00 AM EDT - 3 years ago

The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth

Jul 13, 2023, 9:00 AM EDT - 3 years ago

Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update

Jun 28, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements

Jun 12, 2023, 8:01 AM EDT - 3 years ago

Creative Medical Technology Announces $2 Million Share Repurchase Program

Jun 9, 2023, 12:30 PM EDT - 3 years ago

Creative Medical Technology Holdings Announces Reverse Stock Split

May 31, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform

May 22, 2023, 8:30 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development

May 18, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Apr 12, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

Mar 23, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes

Mar 21, 2023, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development

Mar 7, 2023, 8:00 AM EST - 3 years ago

Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201

Feb 14, 2023, 8:00 AM EST - 3 years ago

Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

Feb 8, 2023, 8:00 AM EST - 3 years ago

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

Nov 3, 2022, 7:30 AM EDT - 3 years ago

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

Oct 20, 2022, 8:00 AM EDT - 3 years ago

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line

Sep 26, 2022, 8:00 AM EDT - 4 years ago

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

Jul 28, 2022, 7:30 AM EDT - 4 years ago

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Jun 15, 2022, 8:30 AM EDT - 4 years ago

Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform

Apr 29, 2022, 8:40 AM EDT - 4 years ago

Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 20, 2022, 8:30 AM EDT - 4 years ago

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Apr 12, 2022, 8:30 AM EDT - 4 years ago

Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World

PraxisTrade Jun. 8 at 12:04 PM

$ICU $PLBY $CELZ $CX ss

0 · Reply

FroNOBaggins Jun. 2 at 8:07 PM

0 · Reply

Bobby_J_Bomb May. 30 at 1:57 PM

$CELZ right now,the next major catalyst could be phase 3 enabling data. This isnt like previous spikes,this would be a game changer and a true path to legitimacy.

1 · Reply

tonneke May. 28 at 4:30 PM

$CELZ My average is $2.06, is that low or ???? 🤷‍♂️

3 · Reply

tonneke May. 27 at 10:19 AM

$CELZ A little bit of news would be nice. 🥳🎉

1 · Reply

H177 May. 22 at 4:44 PM

$CELZ

0 · Reply

H177 May. 22 at 4:42 PM

$CELZ

0 · Reply

tonneke May. 22 at 2:06 PM

$CELZ slowly but still

0 · Reply

Peterb3346 May. 22 at 1:45 PM

$CELZ finally starting to get interesting

0 · Reply

H177 May. 19 at 11:40 PM

$CELZ https://www.biodefenseinc.com/

2 · Reply

Keith14 May. 19 at 8:57 PM

$CELZ What are odds on buyout?

0 · Reply

Stock85 May. 18 at 9:58 PM

$CELZ worst stock I ever invested in

2 · Reply

Kjstock May. 18 at 6:32 PM

$CELZ I think we are almost ready for the next leg up.

0 · Reply

Kjstock May. 15 at 12:09 AM

$CELZ I wish that this was us! https://scitechdaily.com/scientists-reverse-stroke-damage-using-stem-cells-in-breakthrough-study/

1 · Reply

jcooptechit May. 14 at 7:01 PM

$CELZ MAY BE NEARING A MAJOR BIOTECH INFLECTION POINT Creative Medical Technology is heading into a key May 2026 catalyst with top-line Phase 2 data expected for CELZ-201-DDT in chronic low-back pain linked to DDD. 🔸 Phase 2 clinical readout pending 🔸 Chronic pain / DDD = massive market 🔸 Multiple active Phase 2 programs 🔸 DSMB previously supported trial continuation 🔸 No Phase 3 results yet, so this is still early — but high-impact Strong data could quickly change the CELZ narrative and bring serious attention back to its regenerative medicine platform. This next update could be the spark. Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $ABEO $ALLO $AUTL $CARM

0 · Reply

JTE_Theta May. 14 at 5:38 PM

Everyone's chasing AI stocks. Meanwhile $CELZ is quietly running one of the most interesting clinical pipelines in small cap biotech. Creative Medical Technology Holdings, $8.5M market cap. And a pipeline that punches way above its weight. Here's the story 🧵 79% of back pain patients hit meaningful improvements in pain & function. DSMB cleared. Zero safety flags. Then April 2026 - Ultrasome drops a 93% response rate in knee OA. Cell-free. Scalable. Whole new market unlocked. WHO has assigned INNs to TWO separate programs. Rare for any micro cap. Topline ADAPT data + T1 Diabetes readout both expected NOW. $20 B+ spinal market. FDA Fast Track. 60+ patents. Trading at $2.20 The market hasn't priced this in yet ommunicated Disclaimer:http://tinyurl.com/bdduhp5k

0 · Reply

jcooptechit May. 14 at 2:42 PM

$CELZ COULD BE ONE CATALYST AWAY FROM A MAJOR MOMENTUM RE-RATE Creative Medical is tightening right as CELZ-201-DDT Phase 2 results for chronic low-back pain are expected in May 2026. Key levels on watch: * Accumulation: $1.70–$1.82 * Reaccumulation: $2.02–$2.20 * Breakout: $2.32 * Major Resistance: $2.72 🎯 Target Zone: $3.31–$3.68 The roadmap is simple: hold $2.02–$2.20, reclaim $2.32, attack $2.72, then eyes on $3.31+ With Phase 2 results potentially due any day now, volume confirmation could turn this setup from quiet accumulation into a serious catalyst-driven move. Keep CELZ locked in. Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $VTGN $LCTX $ATHX.X $PSTV

0 · Reply

Bobby_J_Bomb May. 14 at 12:38 AM

$CELZ will find out soon if we're going to Phase 3! Feast or famine.

0 · Reply

H177 May. 13 at 9:51 PM

$CELZ

0 · Reply

4Realz May. 12 at 1:30 PM

$CELZ 🤣

0 · Reply

H177 May. 11 at 1:54 PM

$CELZ

0 · Reply

Kjstock May. 10 at 3:48 AM

$CELZ I don’t have time to run through it but they dropped the latest 10Q https://www.sec.gov/Archives/edgar/data/1187953/000147793226002893/celz_10q.htm

2 · Reply

Market Cap	7.62M
Revenue (ttm)	10,000.00
Net Income (ttm)	-6.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-60,000.00%
Debt to Equity Ratio	0.00

Volume	30,890
Avg Vol	67,440
Day's Range	N/A - N/A
Shares Out	3.70M
Stochastic %K	14%
Beta	1.84
Analysts	Sell
Price Target	$20.00